Use of Everolimus in Liver Transplantation: Recommendations From a Working Group by DE SIMONE, Paolo
ReviewUse of Everolimus in Liver Transplantation:
Recommendations From a Working Group
Paolo De Simone, MD, PhD,1 Stefano Fagiuoli, MD,2 Matteo Cescon, MD, PhD,3 Luciano De Carlis, MD, PhD,4
Giuseppe Tisone, MD, PhD,5 Riccardo Volpes, MD,6 Umberto Cillo, MD, PhD,7 and Consensus Panel
Abstract: Immunosuppression after liver transplantation (LT) is presently based on use of calcineurin inhibitors (CNI), although
they are associated with an increased incidence of renal dysfunction, cardiovascular complications, and de novo and recurrent
malignancies. Over the past decade, mammalian target of rapamycin inhibitors have received considerable attention as immuno-
suppressants because they are associated with a more favorable renal profile versus CNI, as well as antiproliferative activity in clin-
ical studies. Comprehensive guidelines on use of everolimus (EVR) in LTare still lacking. In Italy, a project, named Everolimus: the
road to long-term functioning, was initiated to collect the experience on EVR after LTwith the aim of providing guidance for trans-
plant clinicians. Herein, recommendations by this national consensus group, based on Delphi methodology, are presented. Con-
sensus was reached on 20 of the 23 statements proposed, and their level of evidence, grade of recommendation, and percent of
agreement are reported. Statements are grouped into 4 areas: (A) renal function; (B) time of EVR introduction, CNI reduction and
elimination, and risk for graft rejection; (C) antiproliferative effects of EVR; and (D) management of EVR-related adverse events.
The high level of consensus shows that there is good agreement on the routine use of EVR in predefined clinical scenarios,
especially in light of posttransplant nephrotoxicity and other adverse events associated with long-term administration of CNIs.
(Transplantation 2017;101: 239–251)Immunosuppression after liver transplantation (LT) is cur-rently based on use of calcineurin inhibitors (CNI) with
a resulting increased incidence of renal dysfunction, cardio-
vascular complications, and de novo and recurrent malig-
nancies.1-5 Calcineurin inhibitor–related nephrotoxicity is
the most frequent cause of renal dysfunction after LT and is
associated with a 4.55-fold increased risk of death.2,6,7 Strat-
egies of CNI reduction andwithdrawal have recently been in-
troduced in clinical practice in view of preventing or limiting
CNI-related toxicities and commonly include use of antime-
tabolites (azathioprine and mycophenolic acid derivatives),
the anti–interleukin-2 receptor antibody basiliximab, and the
mammalian target of rapamycin inhibitors (mTORi), everoli-
mus (EVR), and sirolimus (SIR), alone or in different combi-
nation schedules.7Received 5 April 2016. Revision received 10 June 2016.
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act on different sites of the T cell activation pathway.8
Mammalian target of rapamycin inhibitors are selective in-
hibitors of the mTOR complex, which is a serine-threonine
kinase with a key role for cell metabolism.8 The activity of
mTOR is upregulated in a number of different cancers, and
EVR reduces levels of vascular endothelial growth factor,
which potentiates angiogenic processes. In addition to its ef-
fects on T cells, EVR is a potent inhibitor of growth and pro-
liferation of tumor cells, endothelial cells, fibroblasts, and
blood vessel–associated smooth muscle cells.
The pharmacokinetic profile of EVR has a shorter termi-
nal half-life versus SIR (about 30 vs 60 hours), and steady-
state trough levels are reached quicker (4 vs 6 days). This
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TABLE 1.
Summary of clinical studies on EVR in de novo liver transplant recipients
Author Year Comparator N Duration Results
Levy et al15 2006 EVR vs placebo 119 36 mo CyA + EVR provides similar
efficacy versus CyA + placebo
Masetti et al16 2010 EVR monotherapy vs CyA-based
immunosuppression
78 12 mo EVR monotherapy provides similar
efficacy and better renal function
Fischer et al17 2012 EVR after conversion from
CNIs vs continued CNIs
203 12 mo EVR monotherapy provides similar
efficacy and better renal function
Sterneck et al14 2014 EVR and discontinue CNI,
or continue their current
CNI-based regimen at 4 wk posttransplant
81a 3 y Efficacy results and improved
renal function maintained
De Simone et al18 2012 (i) EVR initiation with TAC elimination;
(ii) EVR initiation with reduced-exposure TAC;
(iii) standard-exposure TAC
719 12 mo EVR + rTAC provides similar
efficacy and better renal function
Saliba et al13 2013 Extension of the above
study by De Simone et al.18
719 24 mo Efficacy results and improved
renal function profile maintained
a Eligible patients who were followed for 3 years.
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exposure-response relationship have shown that EVR has a
relatively narrow therapeutic window of 3 to 8 ng/mL,
and monitoring of drug trough levels is warranted to ad-
just dose levels.11,12
Recent studies on mTORi have shown that they are asso-
ciated with superior renal function versus CNI in de novo
and maintenance LT recipients.13,14 Table 1 summarizes the
most relevant clinical studies on EVR in de novo LT.
The use of EVR in de novo LT recipients has been recently
approved based on the results of De Simone et al.18 in which
EVR was introduced at day 30 (±5) after surgery. The 2-year
results of the extension period have recently demonstrated
that early introduction of EVR with reduced-exposure tacro-
limus (TAC) at 1month significantly improved renal function
versus standard TAC exposure.13 The 3-year results of the
multicenter, Preservation of Renal Function in Liver Trans-
plant Recipients with Certican Therapy study showed the
possibility to discontinue CNI between 8 and 16 weeks after
surgery and confirmed sustained preservation of renal func-
tion vs. patients on CNI.14TABLE 2.
Summary of clinical studies on conversion to EVR during the ma
Author Year
Comparator/
study design
Castroagudin et al22 2009 Prospective study
De Simone et al21 2009 Prospective study
De Simone et al19 2009 EVR with CNI
reduction vs. EVR
and CNI discontinuation
Saliba et al20 2011 Retrospective analysisEvidence on conversion from CNI- to EVR-based immu-
nosuppression is reported in Table 2, with late conversion re-
ferring to patients 6months or longer after transplantation.19 In
145 maintenance (≥12 months) LT patients randomized to
EVR introduction with CNI reduction or discontinuation
(n = 72) versus CNI reduction (≤50%) (n = 73), 80% of pa-
tients on EVR could discontinue CNI 6 months thereafter.19 A
multicenter, retrospective study on EVR in real-life clinical prac-
tice reported on 240 patients converted from CNI to EVR in
France.20 About 60% of patients were converted to EVR
monotherapy with a very low risk of acute rejection and an ac-
ceptable safety profile. Collateral studies in selected mainte-
nance LT recipients confirmed that conversion to EVR
monotherapy was feasible in 75% of cases and associated with
improvement in renal function.21
Because of the recent approval of EVR for LT and the rel-
atively limited number of available studies, comprehensive
guidelines are still lacking. Compared with many other coun-
tries worldwide, Italy has a solid and long-standing experi-
ence in the optimal strategies on the practical clinical use of
EVR, which began in 2006. In Italy, off-label use of EVR inintenance period in liver transplant recipients
N Duration Results
19 360 d Conversion to EVR provides
improvement in renal function
40 12 mo Conversion to EVR provides
improvement in renal function
145 6 mo Conversion to EVR
monotherapy is feasible, safe,
but associated with minimal
improvement in renal
function versus CNI reduction
240 12 mo Conversion to EVR-based
immunosuppression is associated
with improved renal function
FIGURE 1. The consensus methodology is illustrated. This was a 3-step process incorporating a modified Delphi method and based on the
National Plan Guide for Consensus Meeting.23
© 2016 Wolters Kluwer De Simone et al 241LT was allowed before its official registration thanks to spe-
cific legislation (law 648/96) and based on evidence of its ef-
ficacy in this setting. This educational initiative included
preparation of a consensus document with evidence-based
recommendations on use of EVR after LT, in view of guiding
transplant clinicians in general and special clinical settings.
The current article reports the set of recommendations that
were issued by this national consensus group in Italy.
MATERIALS AND METHODS
Study Design
In November 2014, the educational initiative, Everolimus:
the road to long-term functioning, was set up in Italy to col-
lect all national experiences on use of EVR in kidney and
LT, address priorities and challenges with use of EVR in clin-
ical practice, and introduce practice guidelines. In the setting of
LT, the scientific committee (SC) members (see Appendix
A) opted to draft a set of evidence-based consensus statements
and recommendations to guide use of EVR and help clinicians
manage immunosuppression-related complications after LT.
The SC of the project was composed of Italian experts in
the field of LT as demonstrated by their publication re-
cords, participation in national meetings and clinical trials,
overall expertise, and academic rank, in addition to expe-
rience with EVR.Development of Consensus Statements
and Recommendations
The consensus methodology is illustrated in Figure 1,
consisting of a 3-step process incorporating a modified
Delphi method, which took place between November
2014 and January 2015.Step 1
In November 2014, in the wake of the official approval of
EVR in adult LT, a group of transplant physicians (ie, the SC;
see Appendix A) invited all of the Italian liver transplant centers
to participate in a consensus meeting to define recommenda-
tions on use of EVR-incorporating immunosuppression. For
this initiative, the SC: (1) designed the consensus methodology
according to the National Plan Guide for Consensus Meeting,
and based on what was published elsewhere23,24; (2) appointed
amultidisciplinarypanel of experts (seeAppendixA); and (3) in-
vited the directors of each transplant center to appoint either a
surgeon or a transplant hepatologist to be part of 2 working
groups for selection of topics relevant to clinical practice (see
Appendix A).
According to the guidelines for consensus recommenda-
tions,23 the SC was divided into 2 groups: 2 members were
part of the expert panel, whereas 5 acted as coordinators
(core group) of the consensus methodology. Although 5
TABLE 3.
Levels of evidence based on the Oxford Centre for Evidence-Based Medicine
Level Diagnosis Differential diagnosis/symptom prevalence study
1a • SR (with homogeneity) of level 1 diagnostic studies; SR (with homogeneity) of prospective cohort studies
• (CDR) with 1b studies from different clinical centers
1b Validating cohort study with good reference standards;
or CDR tested within 1 clinical center
Prospective cohort study with good follow-up
1c Absolute SpPins and SnNouts All or none case-series
2a SR (with homogeneity) of level >2 diagnostic studies SR (with homogeneity) of 2b and better studies
2b • Exploratory cohort study with good reference standards; Retrospective cohort study, or poor follow-up
• CDR after derivation, or validated only
on split-sample or databases
2c — Ecological studies
3a SR (with homogeneity) of 3b and better studies SR (with homogeneity) of 3b and better studies
3b Nonconsecutive study; or without
consistently applied reference standards
Nonconsecutive cohort study or very limited population
4 Case-control study, poor or
nonindependent reference standard
Case-series or superseded reference standards
5 Expert opinion without explicit critical appraisal,
or based on physiology, bench research
or “first principles”
Expert opinion without explicit critical appraisal,
or based on physiology, bench research or “first principles”
SR, systematic review; CDR, clinical decision rule.
TABLE 4.
Grades of recommendation
Grades Evidence base
A Consistent level 1 studies
B Consistent level 2 or 3 studies
or extrapolation from level 1 studies
C Level 4 studies or extrapolation
from level 2 or 3 studies
D Level 5 evidence or troublingly
inconsistent or inconclusive studies of any level
The strength of each recommendation depends on the category of the evidence supporting it and is
graded according to the Oxford Centre for Evidence-Based Medicine
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tion,25 19 experts were contacted and asked to participate
in consensus development. All 19 provided consent and
agreed to participate. Panel experts were chosen to repre-
sent professional groups that directly influence patient care
and would benefit from clinical practice guidelines. Panel
members were identified from national institutions and se-
lected based on their clinical and research expertise in the
management of immunosuppression. Eligibility criteria
for transplant physicians included at least 2 of the following:
10-year experience or longer in liver transplant surgery or trans-
plant hepatology, direct responsibility inmanagement of immu-
nosuppression, previous participation in consensus meetings,
serving as national and/or international SC members, serving
as editor for transplant journals, and participation in phase 2
or phase 3 immunosuppressive trials. Nontransplant experts
were selected from previous national consensus meetings.26
The panel consisted of 7 transplant surgeons, 6 transplant
hepatologists, 1 experienced hepatologist, 1 immunolo-
gist, 1 biostatistician, 1 bioethicist, 1 hospital pharmacolo-
gists, and 1 patients' representative (see Appendix A). Panel
members were not involved in the process of selecting or
drafting the statements.
In November 2014, the core group carried out a literature
search. The PubMed database was searched with no lan-
guage limitations until October 31, 2014. Multiple searches
were performed using combinations of the following terms:
liver transplant, transplant, immunosuppression, mTOR,
mTORi, rapamycin, EVR, SIR, renal dysfunction, renal
failure, chronic kidney disease, diabetes mellitus, hyperlipidemia,
dyslipidemia, hypercholesterolemia, hypertriglyceridemia, he-
patic artery thrombosis, oral sores, oral ulcers, mucositis, stoma-
titis, pneumonitis, interstitial lung disease, wound dehiscence,
proteinuria, leukopenia, thrombocytopenia, malignancy, neo-
plasm, cancer, skin cancer, Kaposi sarcoma, hepatocellular carci-
noma (HCC), and cholangiocarcinoma. The reference lists ofall articles were checked manually for additional citations
and gray literature.
Two members of the core group screened all titles and ab-
stracts to discard irrelevant ones. A third member of the core
group resolved conflicts. Articles from the literature search
were included if they described use of EVR-based immuno-
suppression in de novo or maintenance adult LT recipients.
Full texts of relevant studies were retrieved and reviewed
for eligibility. Each reference was graded according to the
quality of their content (Table 3). All retrieved references
were circulated among the transplant center representatives
before the face-to-face meeting.Step 2
On November 26, 2014, the transplant center represen-
tatives and the core group convened in Milan, Italy, for a
face-to-face meeting (see Appendix A). The participants
were split into 2 working groups. The groups provided
feedback on the retrieved references and identified 4 areas
© 2016 Wolters Kluwer De Simone et al 243of interest: (A) renal function; (B) time of EVR introduc-
tion, CNI reduction and elimination, and risk for graft
rejection; (C) antiproliferative effects of EVR; and
(D) EVR-related adverse events. At the end of the day,
the participants arranged a set of 23 preliminary state-
ments to be presented at the final consensus meeting.
In December 2014, a draft document containing the
list of statements was circulated by email among the core
group members with the intention to clarify any redun-
dancy or issues regarding comprehension or syntax of
each statement.Step 3
The consensus meeting took place on January 28, 2015, in
Milan, Italy. The participants included the 19 panel members
and the SC. Each scientific coordinator involved in drafting
of the recommendations presented the background evidence
and proposed the relative statements (Table 4). Panel experts
were given the opportunity to provide comments and suggest
additional items that might not have been included when de-
veloping the initial list of statements. Eventually, the consen-
sus meeting coordinators amended the statements as per the
experts' advice in a separate meeting room.Modified Delphi Consensus Process
Each of the 19 panel members scored the proposed con-
sensus statements by a show of hands on a Likert scale from
1 to 5 as per the following: 1, strongly disagree; 2, disagree; 3,
neutral; 4, agree; and 5, strongly agree. For the purposes of
the consensus statement, agreement among respondents of
70% or greater for each statement (expressed as the percent-
age of respondents scoring an item either 4 [somewhat agree]
or 5 [agree]) was considered to represent consensus. This de-
gree of agreement is based on standards in previously reported
Delphi studies.27,28Role of Pharmaceutical Industry
Novartis Italia, SpA (Origgio, Varese, Italy) provided fi-
nancial support for development of field work for the 2 con-
sensus meetings. The Novartis staff did not take part in
selecting and recruiting panel experts and participants to
the consensus process; nor in the assignment of tasks among
SC and working group members; nor in the analysis and in-
terpretation of literature data, nor in the development and
drafting of the recommendations. The Novartis staff was
not involved in writing the article or in the decision to submit
the article for publication. All of the authors were signifi-
cantly involved in these activities.RESULTS
Consensus was reached on 20 (86.9%) of the 23 state-
ments proposed. The approved statements, their level of
evidence, grade of recommendation (if applicable), and
percent of agreement are herein reported. The statements
are grouped into 4 areas: (A) renal function; (B) time of
EVR introduction, CNI reduction and elimination, and
risk for graft rejection; (C) antiproliferative effects of
EVR; and (D) management of EVR-related adverse events.(A) Renal Function
Level of evidence, 1b; grade of recommendation, A; agree-
ment, 88%.Statement 1: Renal-sparing immunosuppressive
strategies for LT recipients include the following
options13,14,16-18, 29:
• A triple or a quadruple regimenwith use of induction agents
in association with antimetabolites and delayed introduc-
tion of CNI (within 5-10 days after surgery) ± steroids;
• EVR-facilitated CNI reduction starting 30 (±5) days
after transplantation;
• Early (≤10 days) use of EVR to reduce CNI exposure.Comment
Several studies have investigated the efficacy, safety of
implementation of renal-sparing immunosuppressive
strategies usually including a triple or quadruple regimen
with use of antimetabolites, and induction agents in com-
bination with CNI and steroids.29 Recently, 2 large multi-
center, randomized, open-label trials have investigated
EVR-facilitated CNI reduction and stepwise withdrawal
from 1 to 4 months after transplantation and showed im-
proved renal function at 3 years for patients on reduced
CNI exposure13,18 or on EVR monotherapy.14,17 One recent
single-center experience suggested the feasibility of stepwise
elimination of CNI starting 10 days after surgery.16Statement 2: EVR-facilitated reduction of CNI
early (305 days) or very early (10 days) after
transplantation improves renal function at 1 and
3 years.13,14,16-18Level of evidence, 1b; grade of recommendation, A;
agreement, 88%.Comment
Based on current evidence, patients receiving renal-
sparing immunosuppression at an early (30 ± 5 days) or
very early (≤10 days) time after transplantation are ex-
pected to get 8 to 12mL/min per 1.73m2 improvement in re-
nal function at 12 months after transplantation.13,14,16-18
Such improvement is confirmed throughout longer follow-
up periods (3 years) in studies on EVR.14,30 However, it is
important to note that this evidence is derived from studies
enrolling patients with high renal function at transplanta-
tion. In the H2304 study trial, mean estimated glomerular
filtration rate at transplantation was about 80 mL/min
per 1.73 m2,18 whereas it was about 76 mL/min per
1.73 m2 in both the PROTECT trial17 and in the study
by Masetti et al.16 Currently, evidence in large group of
244 Transplantation ■ February 2017 ■ Volume 101 ■ Number 2 www.transplantjournal.compatients with deteriorated renal function at transplantation is
still lacking.Statement 3: Delaying renal-sparing intervention
strategies until glomerular filtration <60mL/min
per 1.73 m2 is associated with only minor
improvement in renal function.19,31,32Level of evidence, 2; grade of recommendation, B;
agreement, 94%.
Comment
Withholding renal-sparing immunosuppressive interven-
tions until renal function drops below 60 mL/min per
1.73 m2 is associated with little improvement in renal func-
tion in 2 series on conversion from CNI to EVR19 and SIR.31
(B) Time of EVR Introduction, CNI Reduction and
Elimination, and Risk for Graft RejectionStatement 4: In LT, early (30  5 days) CNI
reduction with EVR introduction is as effective
and safe as standard-exposure CNI
immunosuppression. CNI reduction facilitated by
EVR can be implemented.13,18Level of evidence, 1b; grade of recommendation, A;
agreement, 90%.
Comment
Based on recent evidence, CNI reduction facilitated by
EVR initiation can be safely implemented from day 30 af-
ter LT, even in the presence of CNI-related renal dysfunc-
tion (as per serum creatinine >1.5 mg/dL, an estimated
glomerular filtration rate <60 mL/min per 1.73 m2 and/or
any other decline in renal function deemed clinically
relevant).13,18Statement 5: CNI withdrawal is associatedwith a
10 20% risk of acute rejection of the liver graft
depending on time of discontinuation after
LT.13,14,16-19,21,30,31Level of evidence, 2; no recommendation applicable;
agreement, 88%.
Comment
Current data suggest that the risk of acute rejection of
the liver graft upon CNI withdrawal facilitated by EVR
introduction depends mainly on the time since transplant.
In one of the largest studies on de novo use of EVR after
LT (H2304), the cumulative 12-month incidence of acute
rejection was 4.1% among patients on EVR+ reduced
TAC (rTAC) versus 10.7% for patients on TAC versus
19.9% for patients who discontinued TAC. Incidence of
treated biopsy-proven acute rejection (tBPAR) was 2.9%in EVR + rTAC patients versus 7.0% for TAC versus 16.5%
for patients who discontinued TAC.18 At 24 months,
the cumulative incidence of acute rejection was 6.1%
for EVR + rTAC versus 13.3% for TAC control versus
26.4% for patients who discontinued TAC, whereas tBPAR
was reported in 4.8%, 7.7%, and 19.9% of EVR + rTAC,
TAC control, and TAC elimination patients, respectively.13
In the 36-month follow-up study (H2304E1), the cumula-
tive incidence of acute rejection was 7.3%, 17.7%, and
26.8% for EVR + rTAC, TAC control, and TAC elimina-
tion, whereas tBPAR was 4.8%, 9.2%, and 21.5%, respec-
tively.30 Maintenance studies report a variable acute
rejection risk from almost nil to 15%,19-21 according to
the interval from transplantation and mode of tapering.
To date, no information is available on the impact of na-
tive liver disease on the risk of acute rejection upon CNI
withdrawal both in de novo and in maintenance trans-
plant populations.Statement 6: Conversion to EVRmonotherapy
for CNI-related renal toxicity is feasible in 80% of
patients at12months after liver transplantation.
The impact on renal function of conversion
strategies is dependent on the severity of renal
impairment and timing of conversion.19-22,33Level of evidence, 2; no recommendation applicable;
agreement, 76%.Comment
Data from randomized trials inmaintenance (≥12months)
LT recipients confirm that feasibility of conversion from
CNI-based to EVRmonotherapy is 80%at 6 and 12months,
but that the impact on renal function is poor for patients with
deteriorated renal function, for example, calculated creati-
nine clearance <60 mL/min.19 Consistent information is de-
rived from a randomized study on conversion to SIR,31 and
from single-center retrospective series and cohorts.22,33Statement 7: Due to different pharmacokinetic
interactions, TAC should not be reduced before
EVR is in the target blood range (3 ng/mL),
whereas cyclosporine A (CyA) should be
reduced upon administration of EVR.11,15Level of evidence, 2; grade of recommendation, B;
agreement, 95%.Comment
Whereas there is virtually no pharmacokinetic interaction
between EVR and TAC, EVR produces a 4-fold increase in
CyA area under the concentration-time curve (AUC). Upon
introduction of EVR in patients on CyA, concomitant CyA
reduction is therefore warranted.11,12,15
© 2016 Wolters Kluwer De Simone et al 245(C) Antiproliferative Effects of EVRStatement 8: EVR and SIR share similar
antiproliferative properties both in vitro and in
vivo, with EVR presenting advantages due to its
shorter half-life.9-11,34-37Level of evidence, 2; no recommendation applicable;
agreement, 76%.
Comment
Sirolimus and EVR have similar antiproliferative prop-
erties.9-11,34-37 The 2 drugs share a common molecular
structure, with EVR having a shorter terminal half-life
and quicker steady state versus SIR.9-12 These latter prop-
erties might represent an advantage for EVR versus SIR in
clinical practice, although there are no direct comparative
studies, with trough blood level dose adjustments being
quicker for EVR versus SIR.12Statement 9: Use of mTORi is associated with a
reduced incidence of de novomalignancies after
kidney, heart, and LT.38-41Level of evidence, 3; no recommendation applicable;
agreement, 95%.
Comment
Experimental and clinical evidence confirm the antipro-
liferative properties of the mTORi SIR and EVR. Although
no randomized, controlled trial has, to date, demonstrated
superiority of mTORi-based immunosuppression in reduc-
ing the incidence of de novo and recurrent malignancies af-
ter solid organ transplantation in general, and LT in
particular, use of mTORi is supported by retrospective,
cohort, and registry data analysis.38-40 The expert panel
agreed that all LT recipients at high risk of de novomalignan-
cies (ie, human herpesvirus-8-positive patients; alcoholic cir-
rhosis patients; patientswith concurrent inflammatory bowel
disease; recipients of grafts from donors at risk of transmis-
sion of malignancies; Epstein Barr virus-DNA–negative re-
cipients, and recipients developing Epstein Barr virus-DNA
positivity after transplantation) may warrant mTORi-based
immunosuppression.Statement 10: In LT, mTORi can be used as
immunosuppressants to reduce the risk of
posttransplant HCC recurrence.40-42Level of evidence, 3; grade of recommendation, C;
agreement, 95%.
Comment
There is sufficient preclinical and clinical evidence on the
role of mTORi to control recurrence and growth of HCC.
Based on currently available data, patients at high risk forHCC recurrence as per explant histology (ie, tumor grading,
vascular infiltration, and so on) represent the ideal target
population for a policy of prophylaxis of tumor recurrence
with mTORi. Although multivariate analysis of a registry
population of adult LT recipients comparing 2491 HCC
patients with 12 167 non-HCC recipients has shown that
mTORi are associated with improved posttransplant pa-
tient survival among patients with HCC at transplant,40
recent reports have mitigated these findings.43,44 A pro-
spective, randomized clinical trial on SIR-based immuno-
suppression has reported a benefit only for patients
within Milan criteria,43 and a recent analysis of the Scien-
tific Registry of Transplant Recipients on patients with
SIR-based maintenance immunosuppression has suggested
reductions in recurrence and cancer-specific mortality, but ef-
fects of SIR seem to be modified by age at transplantation.44Statement 11: Use of mTORi is recommended for
patients with de novo malignancies after
LT.40,41,45-47Level of evidence, 2; grade of recommendation, B;
agreement 95%.
Comment
Mammalian target of rapamycin inhibitors are indi-
cated in LT patients with de novo malignancies after trans-
plantation. Current evidence supports use of either mTORi
monotherapy or combined immunosuppression with
reduced-exposure CNI, depending on individual risk (eg,
time since transplant, indication to transplantation, age at
transplantation, and so on).40,41,45-47Statement 12: In patients with recurrent HCC
after LT, it is recommended to introduce EVR
together with CNI reduction or withdrawal, due
to its combined immunosuppressive and
antiproliferative properties.40,41,48-50Level of evidence, 5; grade of recommendation, B; agree-
ment, 80%.Statement 13: In patients with recurrent HCC
after LT, use of EVR is recommended unless
clinically contraindicated and irrespective of
implementation of other treatment modalities
(eg, surgery, radiology-guided tumor ablation,
transarterial chemoembolization, or transarterial
radioembolization).40,41,48-50Level of evidence, 5; grade of recommendation, B;
agreement, 95%.
Comment on Statements 12 and 13
Recurrence of HCC after LT is still associated with dis-
mal outcomes.41 Everolimus has antiproliferative activity
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ports suggest that mTORi should be introduced for pa-
tients with recurrent HCC in the posttransplant course to
slow disease progression.40,41,48-50 In this regard, the re-
cent Sirolimus after Liver Transplantation study investi-
gated whether mTORi-based immunosuppression improves
outcomes in LT candidates with HCC.43 In this long-term,
prospective clinical trial, 525 LT recipients with HCC initially
receiving mTORi-free immunosuppression were randomized
4 to 6 weeks after transplantation to mTORi-free immuno-
suppression or SIR. The trial showed no difference in overall
survival between the 2 groups after 8 years, although
there was significant benefit of mTORi-based immuno-
suppression in improving recurrence-free survival and
overall survival in the first 3 to 5 years, especially in
low-risk patients.43
There is no evidence regarding the role of mTORi as
neoadjuvant or adjuvant agents in combination with surgery
or radiology-based treatment modalities for posttransplant
recurrent HCC, but literature data suggest patients can be
treated with either modality unless mTORi are clinically con-
traindicated (eg, coexisting proteinuria, severe dyslipidemia,
neutropenia, and so on).40,41,48-50Statement 14: For LTpatientswith recurrentHCC
not amenable to surgical or radiological
treatment, a combination regimen with EVR and
sorafenib shows a pathophysiological
rationale.40,41,48-50Level of evidence, 5; no recommendation applicable;
agreement, 78%.
Comment
This recommendation is based on the complementary
effect of the 2 agents on the molecular pathways involved
in HCC.48 However, use of such a regimen is recom-
mended only for experienced LT specialists or oncologists
due to the potential for sorafenib-related and EVR-
related side effects.48-50
(D) Management of EVR-Related Adverse EventsStatement 15: In transplant patients, EVR-related
dyslipidemia is dose-dependent.15,51Level of evidence, 1; no recommendation applicable;
agreement, 100%.Statement 16: When dyslipidemia is observed in
LT recipients on treatment with EVR at trough
levels higher than the recommended ranges
(>8 ng/mL), prompt reduction of EVRoral dose is
warranted.13,18Level of evidence, 2; grade of recommendation, B; agree-
ment, 94%.Statement 17: Dyslipidemia occurring in LT
recipients should be treated (with EVR dose
reduction if trough levels are >8 ng/mL)
irrespective of the time from transplantation.51-53Level of evidence, 5; grade of recommendation, C;
agreement, 94%.Comment on Statements 15, 16, and 17
There is solid evidence in the literature that use of
mTORi in transplant patients is associated with increased
levels of total cholesterol and triglycerides, and that this
adverse event is dose-dependent.15,51 In published ran-
domized, controlled trials dyslipidemia was treated with
reduction of EVR exposure, especially for patients with
higher than the recommended trough levels (3-8 ng/
mL).13,18 It is important to note that the literature data
show no increased use of statins among patients on EVR-
based immunosuppression versus patients on CNI, nor
does any evidence exist suggesting an increased risk of car-
diovascular events for patients on EVR.52Statement 18: The risk of EVR-related proteinuria
(as per >1 g/d) in LT recipients is about 3% at
3 years.13,18,30Level of evidence, 1b; no recommendation applicable;
agreement, 94%.
Comment
Mammalian target of rapamycin inhibitor treatment is
associated with a net increase in protein urinary excre-
tion. In the H2304 study, the overall incidence of protein-
uria as an adverse event was higher in the EVR plus
reduced TAC group than in the standard TAC group
(3.7% vs 0.8%, respectively; P = 0.063), and proteinuria
was the leading cause of study drug discontinuation (8 vs
1 patient).13,18,30 However, the mean urine protein-to-
creatinine ratio remained below the 500 mg/d threshold
until 36 months after transplantation.13,18,30 This is in
part related to the high baseline renal function of the pop-
ulation included the trial.13,18,30 After CNI withdrawal
the incidence of proteinuria can be higher due to both se-
lection of patients with worse baseline renal function and
lack of the vasoconstrictor effect of CNI. Proteinuria
greater than 3 g/d was 9.5% (2/21) in a conversion
study,32 whereas in the PROTECT trial, proteinuria was
reported in 9.9% of EVR-treated patients versus 2.0%
of the patients in the CNI group (P = 0.05).14,17 None of
the cases of proteinuria were considered severe or serious.
In the study of maintenance patients by De Simone et al,19
2 patients (2.7%) discontinued EVR because of proteinuria,
which in both cases was suspected to be related to studymed-
ication. However, there is a suggestion that mTORi-related
proteinuria may well be the harbinger of underlying renal
disease presenting upon CNI elimination or reduction and
due to loss of CNI-related glomerular vasoconstriction, but
© 2016 Wolters Kluwer De Simone et al 247also that it may accelerate progression of renal dysfunc-
tion.19,22,54-56 Patients on mTORi and with proteinuria
greater than 800 mg/d warrant constant monitoring of re-
nal function and EVR discontinuation should be consid-
ered for overt nephrotic proteinuria.19Statement 19: In LT recipients with severe
neutropenia (<1000mm3), leukopenia
(<2000 mm3), or thrombocytopenia
(<50 000 mm3) dose adjustments of EVR or
withdrawal are recommended.13,18,30Level of evidence, 5; grade of recommendation, C;
agreement, 94%.
Comment
In published randomized, controlled trials EVR-related
hematological adverse events were treated with EVR dose
reduction or withdrawal, especially for patients with higher
than the recommended trough levels (3-8 ng/mL).13,18,30Statement 20: EVR-based immunosuppressive
regimens are not associated with an increased
risk of infections compared with standard CNI-
based immunosuppression.13,14,17,18,30Level of evidence, 1b; no recommendation applicable;
agreement, 94%.
Comment
The largest trials on EVR after LT did not show a sta-
tistically significant increase in the incidence of infec-
tious complications for patients on EVR-facilitated
TAC reduction.13,14,17,18,30DISCUSSION
The national consensus group was organized with the
major objective of consolidating national experience on
EVR after LT, based on Delphi methodology, to obtain a
framework for the clinical management of transplant re-
cipients. The national consensus group in Italy reached
broad consensus on 20 statements. However, consensus
was not reached on wound healing adverse events, time
to EVR reduction, or posttransplant proteinuria.
Considering wound healing adverse events, the rates of
incisional hernia and lymphocele have been reported with
mTORi when patients received a high loading dose.57
However, more recent studies using lower doses of an
mTORi without a loading dose have shown that rates of
wound-healing complications do not differ significantly
between mTORi and other immunosuppressive thera-
pies.58 In 2 randomized trials, the incidence of wound
complications and incisional hernia was similar in liver
transplant recipients receiving EVR or CNIs.13,14,17,18,30
A third study reported a higher rate of incisional hernia
in 52 liver transplant recipients receiving EVR compared
with 26 recipients on cyclosporine (46.1% vs 26.9%), al-
though the difference was not significant.59Most complications develop during the first few postop-
erative months. At 30 days or longer posttransplantation,
wounds should be somewhat healed and wound strength
should be improving; the risks of wound complications as-
sociated with newly initiated mTORi therapy at this stage
should be minimal. It was felt that further studies are
needed to explore the impact of EVR on wound healing
in case of an anticipated (<30 days) use after LT.
Any decision on use of EVR in patients with prior sur-
geries and/or at higher risk for wound healing complica-
tions should be tailored on the individual risk-to-benefit ratio.
No consensus could also be reached on the time to EVR re-
duction even though “very early introduction of EVR post-
transplantation (<10 days) has been reported as effective
and safe in two randomized clinical trials.”15,16 This was
deemed to be mostly attributable to differences in interpreta-
tion of what is meant by ‘very early’.
No consensus could also be reached on monitoring of re-
nal function. Although several studies have provided evi-
dence in this regard,13,14,17,18,30 it should be considered that
clinically significant proteinuria (>2 g/day) likely requires
evaluation of EVR dose adjustments and/or withdrawal, in
association with introduction of antiproteinuric drugs (angio-
tensin converting enzyme inhibitors and CNIs) and referral to
renal care specialists.
Not all topics related to the use of EVR-incorporating
immunosuppression after LT could be addressed by the
current initiative. Some issues—such as hepatic artery
thrombosis, diabetes mellitus and cytomegalovirus infec-
tion, and whose incidence is not increased among patients
on EVR versus those—on CNI in large, prospective, ran-
domized trials13,14,17,18,30—were considered less relevant
by the transplant centers' representatives during the initial
face-to-face meeting. Participants in the consensus initiative
were asked to address issues they perceived as challenging
or that deserved clarification in light of the available litera-
ture evidence. Similarly, the antifibrotic properties of EVR
and its potentially favorable impact on hepatitis C virus pro-
gression after transplantation60,61 were not explored by the
current consensus group due to the introduction of novel di-
rect antiviral agents for hepatitis C virus infection in the same
period. The issue of EVR-related interstitial pneumonia,
which was reported in 2% to 5% of patients on EVR in the
H2304 and PROTECT trials,13,14,17,18,30 was not addressed
because its incidence is lower than what was reported in
other solid organ transplant populations (ie, kidney) or in
cancer patients.62,63
A consensus was reached for the majority of statements,
including ongoing treatments, renal function, and de novo
tumors. Everolimus provides a valid therapeutic option for
LT recipients, particularly considering posttransplant neph-
rotoxicity. Additional studies are needed, especially re-
garding the early introduction of EVR and its use in
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University of Bologna Medical Hospital,
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Surgeon
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2 Umberto Cillo, MD PhD Chair
Surgeon General Surgery and liver transplantation;
University of Padua Medical School Hospital, Padua, ItalyCore group
3 Luciano De Carlis, MD PhD Chair
Surgeon Department of General Surgery and Transplantation,
Ca’ Granda Niguarda Hospital, Milan, ItalyCore group
4 Paolo De Simone, MD PhD Hepatobiliary surgery and liver transplantation,
University of Pisa Medical School Hospital, Pisa, ItalySurgeon
Core group
5 Stefano Fagiuoli, MD Chair
Transplant hepatologist Gastroenterology and Transplant Hepatology,
Papa Giovanni XXIII Hospital, Bergamo, ItalyPanel
6 Giuseppe Tisone, MD PhD Chair
Surgeon General and Transplant Surgery,
Department of Experimental Medicine and Surgery,
Tor Vergata University of Rome Medical School Hospital,
Rome, Italy
Core group
7 Riccardo Volpes, MD Division of Transplantation,
Mediterranean Institute for Transplantation and
Advanced Specialized Therapies (ISMeTT), Palermo, Italy
Transplant hepatologist
Panel
The Panel Experts
Number Panel Institution
1 Stefano Fagiuoli, MD Chair
Transplant hepatologist Gastroenterology and Transplant Hepatology,
Papa Giovanni XXIII Hospital, Bergamo, ItalyScientific Committee
2 Riccardo Volpes, MD Division of Transplantation,
Mediterranean Institute for Transplantation and
Advanced Specialized Therapies (ISMeTT), Palermo, Italy
Transplant hepatologist
Scientific Committee
3 Alfonso W Avolio, MD PhD Department of General and Transplant Surgery,
Catholic University of Rome, Rome, ItalySurgeon
4 Patrizia Burra, MD PhD Chair
Transplant hepatologist Multivisceral and Liver Transplantation,
University of Padua Medical Hospital, Padua, Italy
5 Fulvio Calise, MD Chair
Surgeon Hepatobiliary Surgery and Liver Transplantation,
Cardarelli Hospital, Naples, Italy
6 Fabrizio Di Benedetto, MD PhD Chair,
Surgeon Hepatobiliary surgery and Liver Transplantation,
Modena University Hospital, Modena, Italy
7 Giuseppe M Ettorre, MD Chair
Surgeon General and Transplant Surgery,
San Camillo-Forlanini Hospital, Rome, Italy
8 Alfonso Galeota Lanza, MD Gastroenterology and Liver transplantation,
Cardarelli Hospital, Naples, ItalyTransplant hepatologist
9 Luigi Lupo, MD PhD General and Transplant Surgery,
University of Bari Medical School Hospital, Bari, ItalySurgeon
10 Umberto Montin, MD General and Transplant Surgery, University of Verona
Medical School Hospital, Verona, ItalySurgeon
11 Paolo Reggiani, MD General Surgery and Liver Transplantation,
University of Milan Medical School Hospital, Milan, ItalySurgeon
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Number Panel Institution
12 Maria Rendina, MD Gastroenterology,
University of Bari Medical School Hospital, Bari, ItalyTransplant hepatologist
13 Giuliano Torre Chair
Transplant hepatologist Gastroenterology, Bambino Gesù Hospital, Rome, Italy
14 Marco Bozzoli Transplant patient representative
15 Raffaele Bruno, MD PhD Infectious Disease,
University of Pavia Medical School Hospital, Pavia, ItalyHepatologist
16 Giambattista Ippoliti, MD PhD Chair
Immunologist Immunology and Infectious Disease,
Monza Hospital, Monza, Italy
17 Gioacchino Leandro, Biol Biostatistics, IRCSS De Bellis, Bari, Italy
Biostatistician
18 Dario Sacchini, MD PhD Bioethics, Catholic University of Rome, Rome, Italy
Bioethicist
19 Francesca Venturini, Pharm Pharmacology,
University of Milan Medical School Hospital, Milan, ItalyPharmacologist
The Transplant Centers' Representatives
Number Transplant Center Representative Institution
1 Umberto Baccarani, MD PhD General Surgery and Transplantation,
Surgeon University of Udine Medical School Hospital, Udine, Italy
2 Patrizia Boccagni, MD General Surgery and Liver Transplantation,
Surgeon University of Padua Medical School Hospital, Padua, Italy
3 Antonino Castellaneta, MD Gastroenterology, University of Bari Medical School Hospital,
Bari, ItalyTransplant hepatologist
4 Gabriella Cordone, MD Gastroenterology, University Federico II Medical School
Hospital, Naples, ItalyTransplant hepatologist
5 Nicola De Ruvo, MD Hepatobiliary surgery and Transplantation,
University of Modena Medical School Hospital, Modena, ItalySurgeon
6 Giacomo Germani, MD PhD Multivisceral and Liver Transplantation,
University of Padua Medical School Hospital, Padua, ItalyTransplant hepatologist
7 Antonio Giuliani, MD Hepatobiliary surgery and Liver Transplantation,
Cardarelli Hospital, Naples, ItalySurgeon
8 Maria Grazia Lucà, MD Gastroenterology and liver transplantation,
Papa Giovanni XXIII Hospital, Bergamo, ItalyTransplant hepatologist
9 Francesco Lupo, MD General and Transplant Surgery,
San Giovanni Battista Hospital, Turin, ItalySurgeon
10 Jacopo Mangoni, MD General and Transplant Surgery,
Ca' Granda Niguarda Hospital, Milan, ItalySurgeon
11 Matteo Manini, MD Gastroenterology,
University of Milan Hospital, Milan, ItalyTransplant Hepatologist
12 Gianluca Mennini, MD PhD General surgery and Transplantation,
La Sapienza University of Rome Medical School, Rome, ItalySurgeon
13 Roberto Montalti, MD General and Transplant Surgery,
University of Ancona Medical School Hospital, Ancona, ItalySurgeon
14 Erida Nure, MD Department of General and Transplant Surgery,
Catholic University of Rome, Rome, ItalySurgeon
15 Andrea Pietrobattista Liver Unit, Bambino Gesù Hospital, Rome, Italy
Transplant hepatologist
16 Daniele Sforza, MD General and Transplant Surgery,
Department of Experimental Medicine and Surgery,
Tor Vergata University of Rome Medical School Hospital,
Rome, Italy
Surgeon
17 Maria Filippa Valentini, MD General and Transplant Surgery,
University of Bari Medical School Hospital, Bari, ItalySurgeon
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Surgeon
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University Hospital, Modena, Italy; Giuseppe M Ettorre, MD,
General and Transplant Surgery, San Camillo-Forlanini Hos-
pital, Rome, Italy; AlfonsoGaleota Lanza,MD, Gastroenter-
ology and Liver transplantation, Cardarelli Hospital, Naples,
Italy; Luigi Lupo, MD PhD, General and Transplant Sur-
gery, University of Bari Medical School Hospital, Bari, Italy;
Umberto Montin, MD, General and Transplant Surgery,
University of VeronaMedical School Hospital, Verona, Italy;
Paolo Reggiani, MD, General Surgery and Liver Transplan-
tation, University of Milan Medical School Hospital, Milan,
Italy; Maria Rendina, MD, Transplant hepatologist; Gastro-
enterology, University of Bari Medical School Hospital, Bari,
Italy; Giuliano Torre, MD PhD, Gastroenterology, Bambino
GesùHospital, Rome, Italy;Marco Bozzoli, transplant patient
representative; Raffaele Bruno, MD PhD, Infectious Disease,
University of Pavia Medical School Hospital, Pavia, Italy;
Giambattista Ippoliti, MD PhD, Immunology and Infectious
Disease, Monza Hospital, Monza, Italy Gioacchino Leandro,
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Medical School Hospital, Milan, Italy.REFERENCES
1. Felga G, Evangelista AS, Salvalaggio PR, et al. Hepatocellular carcinoma re-
currence among liver transplant recipients within the Milan criteria.
Transplant Proc. 2012;44:2459–2461.
2. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of
a nonrenal organ. N Engl J Med. 2003;349:931–940.
3. Tjon AS, Sint Nicolaas J, Kwekkeboom J, et al. Increased incidence of
early de novo cancer in liver graft recipients treated with cyclosporine: an
association with c2 monitoring and recipient age. Liver Transpl. 2010;
16:837–846.
4. Welker MW, BechsteinWO, ZeuzemS, et al. Recurrent hepatocellular car-
cinoma after liver transplantation - an emerging clinical challenge. Transpl
Int. 2013;26:109–118.
5. Wimmer CD, Angele MK, Schwarz B, et al. Impact of cyclosporine versus
tacrolimus on the incidence of de novo malignancy following liver trans-
plantation: a single center experience with 609 patients. Transpl Int.
2013;26:999–1006.
6. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD)
after orthotopic liver transplantation (oltx) using calcineurin-based
immunotherapy: risk of development and treatment. Transplantation.
2001;72:1934–1939.7. Pham PT, Pham PC, Wilkinson AH. Management of renal dysfunction
in the liver transplant recipient. Curr Opin Organ Transplant. 2009;14:
231–239.
8. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl
J Med. 2004;351:2715–2729.
9. Kirchner GI, Meier-Wiedenbach I, MannsMP. Clinical pharmacokinetics of
everolimus. Clin Pharmacokinet. 2004;43:83–95.
10. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin deriv-
ative: pharmacological properties in vitro and in vivo. Transplantation.
1997;64:36–42.
11. Shihab F, Christians U, Smith L, et al. Focus onmTOR inhibitors and tacro-
limus in renal transplantation: Pharmacokinetics, exposure-response rela-
tionships, and clinical outcomes. Transpl Immunol. 2014;31:22–32.
12. Shipkova M, Hesselink DA, Holt DW, et al. Therapeutic drug monitoring of
everolimus: a consensus report. Ther Drug Monit. 2016;38:143–169.
13. Saliba F, De Simone P, Nevens F, et al. Renal function at two years in liver
transplant patients receiving everolimus: results of a randomized, multi-
center study. Am J Transplant. 2013;13:1734–1745.
14. Sterneck M, Kaiser GM, Heyne N, et al. Everolimus and early calcineurin
inhibitor withdrawal: 3-year results from a randomized trial in liver trans-
plantation. Am J Transplant. 2014;14:701–710.
15. Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of
everolimus in de novo liver transplant recipients: 12- and 36-month
results. Liver Transpl. 2006;12:1640–1648.
16. Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of cal-
cineurin inhibitors and everolimus monotherapy in de novo liver trans-
plant recipients preserves renal function. Am J Transplant. 2010;10:
2252–2262.
17. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled
study to assess the conversion from calcineurin-inhibitors to everolimus
after liver transplantation – PROTECT.Am J Transplant. 2012;12:1855–1865.
18. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacro-
limus improves renal function in de novo liver transplant recipients: a ran-
domized controlled trial. Am J Transplant. 2012;12:3008–3020.
19. De Simone P, Metselaar HJ, Fischer L. Conversion from a calcineurin
inhibitor to everolimus therapy in maintenance liver transplant recipients:
A prospective, randomized, multicenter trial. Liver Transpl. 2009;15:
1262–1269.
20. Saliba F, Dharancy S, Lorho R, et al. Conversion to everolimus in mainte-
nance liver transplant patients: A multicenter, retrospective analysis. Liver
Transpl. 2011;17:905–913.
21. De Simone P, Carrai P, Precisi A, et al. Conversion to everolimus mono-
therapy in maintenance liver transplantation: Feasibility, safety, and impact
on renal function. Transpl Int. 2009;22:279–286.
22. Castroagudin JF, Molina E, Romero R, Otero E, Tome S, Varo E. Improve-
ment of renal function after the switch from a calcineurin inhibitor to evero-
limus in liver transplant recipients with chronic renal dysfunction. Liver
Transpl. 2009;15:1792–1797.
23. Lomas J. Words without action? The production, dissemination, and
impact of consensus recommendations. Annu Rev Public Health. 1991;
12:41–65.
24. Rostom A, Moayyedi P, Hunt R, Canadian Association of Gastroenterology
Consensus G. Canadian consensus guidelines on long-term nonsteroidal
anti-inflammatory drug therapy and the need for gastroprotection: Benefits
versus risks. Aliment Pharmacol Ther. 2009;29:481–496.
25. Lynn MR. Determination and quantification of content validity. Nurs Res.
1986;35:382–382.
26. Cillo U, Burra P, Mazzaferro V, et al. A multistep, consensus-based ap-
proach to organ allocation in liver transplantation: toward a "Blended Prin-
ciple Model". Am J Transplant. 2015;15:2552–2561.
© 2016 Wolters Kluwer De Simone et al 25127. Mahler DA, Selecky PA, Harrod CG, et al. American College of Chest
Physicians Consensus Statement on the management of dyspnea
in patients with advanced lung or heart disease. Chest. 2010;137:
674–691.
28. Zafar SY, CurrowDC, ChernyN, Strasser F, Fowler R, Abernethy AP. Con-
sensus-based standards for best supportive care in clinical trials in ad-
vanced cancer. Lancet Oncol. 2012;13:e77–e82.
29. Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of
reduced-dose tacrolimus, and renal function in liver transplantation: The
‘RESPECT’ study. Am J Transplant. 2009;9:327–336.
30. Fischer L, Saliba F, Kaiser GM, et al. Three-year outcomes in de novo
liver transplant patients receiving everolimus with reduced tacrolimus:
follow-up results from a randomized, multicenter study. Transplantation.
2015;99:1455–1462.
31. Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen
versus continued calcineurin inhibitors in liver allograft recipients: a ran-
domized trial. Am J Transplant. 2012;12:694–705.
32. Watt KD, Coss E, Pedersen RA, Dierkhising R, Heimbach JK, Charlton
MR. Pretransplant serum troponin levels are highly predictive of patient
and graft survival following liver transplantation. Liver Transpl. 2010;16:
990–998.
33. De Simone P, Precisi A, Petruccelli S, et al. The impact of everolimus on
renal function in maintenance liver transplantation. Transplant Proc.
2009;41:1300–1302.
34. Afinitor (everolimus). Summary of prescribing characteristics. Novartis
Pharmaceuticals. Available from: https://www.pharma.us.novartis.com/
product/pi/pdf/afinitor.pdf. Accessed 23 January 2015.
35. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling
in hepatocellular carcinoma.Gastroenterology. 2008;135:1972–1983,
1983 e1971-1911.
36. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal
hormone-receptor-positive advanced breast cancer. N Engl J Med.
2012;366:520–529.
37. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits pri-
mary and metastatic tumor growth by antiangiogenesis: involvement of
vascular endothelial growth factor. Nat Med. 2002;8:128–135.
38. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosup-
pression with target-of-rapamycin inhibitors is associated with a re-
duced incidence of de novo malignancies. Transplantation. 2005;80:
883–889.
39. Piselli P, Serraino D, Segoloni GP, et al. Risk of de novo cancers after trans-
plantation: results from a cohort of 7217 kidney transplant recipients, Italy
1997–2009. Eur J Cancer. 2013;49:336–344.
40. Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppres-
sion is associated with increased survival after liver transplantation for
hepatocellular carcinoma. Hepatology. 2010;51:1237–1243.
41. Cholongitas E, MamouC, Rodriguez-Castro KI, et al. Mammalian target of
rapamycin inhibitors are associated with lower rates of hepatocellular car-
cinoma recurrence after liver transplantation: a systematic review. Transpl
Int. 2014;27:1039–1049.
42. Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving
target. Expert Rev Anticancer Ther. 2009;9:247–261.
43. Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver trans-
plant recipients with hepatocellular carcinoma: a randomized, multicenter,
open-label phase 3 trial. Transplantation. 2016;100:116–125.
44. Yanik EL, Chinnakotla S, Gustafson SK, et al. Effects of maintenance im-
munosuppression with sirolimus after liver transplant for hepatocellular
carcinoma. Liver Transpl. 2016;22:627–634.45. Bilbao I, Sapisochin G, Dopazo C, et al. Indications and management
of everolimus after liver transplantation. Transplant Proc. 2009;41:
2172–2176.
46. Jiménez-Romero C, Manrique A, Marqués E, et al. Switching to sirolimus
monotherapy for de novo tumors after liver transplantation. A preliminary
experience. Hepatogastroenterology. 2011;58:115–121.
47. Vivarelli M, Dazzi A, Cucchetti A, et al. Sirolimus in liver transplant re-
cipients: a large single-center experience. Transplant Proc. 2010;42:
2579–2584.
48. Bhoori S, Toffanin S, Sposito C, et al. Personalized molecular targeted
therapy in advanced, recurrent hepatocellular carcinoma after liver trans-
plantation: a proof of principle. J Hepatol. 2010;52:771–775.
49. De Simone P, Crocetti L, Pezzati D, et al. Efficacy and safety of combina-
tion therapy with everolimus and sorafenib for recurrence of hepatocellular
carcinoma after liver transplantation. Transplant Proc. 2014;46:241–244.
50. Gomez-Martin C, Bustamante J, Castroagudin JF, et al. Efficacy and
safety of sorafenib in combination with mammalian target of rapamycin in-
hibitors for recurrent hepatocellular carcinoma after liver transplantation.
Liver Transpl. 2012;18:45–52.
51. Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of
rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J
Transplant. 2008;8:1384–1392.
52. Holdaas H, Potena L, Saliba F. mTOR inhibitors and dyslipidemia in trans-
plant recipients: a cause for concern? Transplant Rev (Orlando). 2014;29:
93–102.
53. Singh S, Watt KD. Long-term medical management of the liver transplant
recipient: what the primary care physician needs to know.Mayo Clin Proc.
2012;87:779–790.
54. Pillebout E, Nochy D, Hill G, et al. Renal histopathological lesions after
orthotopic liver transplantation (OLT). Am J Transplant. 2005;5:1120–1129.
55. Cozzolino M, Gentile G, Mazzaferro S, et al. Blood pressure, proteinuria,
and phosphate as risk factors for progressive kidney disease: a hypothe-
sis. Am J Kidney Dis. 2013;62:984–992.
56. Iwatsuki S, Esquivel CO, Klintmalm GB, et al. Nephrotoxicity of cyclospor-
ine in liver transplantation. Transplant Proc. 1985;17:191–195.
57. Pengel LH, Liu LQ, Morris PJ. Do wound complications or lymphoceles
occur more often in solid organ transplant recipients on mTOR inhibitors?
A systematic review of randomized controlled trials. Transpl Int. 2011;24:
1216–1230.
58. Nashan B, Citterio F. Wound healing complications and the use of mam-
malian target of rapamycin inhibitors in kidney transplantation: a critical re-
view of the literature. Transplantation. 2012;94:547–561.
59. Montalti R, Mimmo A, Rompianesi G, et al. Early use of mammalian target
of rapamycin inhibitors is an independent risk factor for incisional hernia
development after liver transplantation. Liver Transpl. 2012;18:188–194.
60. Saliba F, Brown RS, Metselaar HJ, et al. Everolimus based immunosup-
pression in hepatitis C virus positive de novo liver transplant recipients:
24-month results from a randomized controlled trial. Liver Transpl. 2013;
19:S100.
61. Villamil FG, Gadano AC, Zingale F, et al. Fibrosis progression in
maintenance liver transplant patients with hepatitis C recurrence:
a randomised study of everolimus vs. calcineurin inhibitors. Liver
Int. 2014;34:1513–1521.
62. Baas MC, Struijk GH, Moes DJ, et al. Interstitial pneumonitis caused by
everolimus: a case-cohort study in renal transplant recipients. Transpl
Int. 2014;27:428–436.
63. Willemsen AE, Grutters JC, Gerritsen WR, et al. mTOR inhibitor-induced
interstitial lung disease in cancer patients: comprehensive review and a
practical management algorithm. Int J Cancer. 2016;138:2312–2321.
